Dr. Sirajunisa Talath

Educational Qualification:

• Ph. D. (Pharmaceutical Chemistry) Rajiv Gandhi University of Health Sciences, Karnataka, Bangalore, India (August 2007)
• M. Pharm. (Pharmaceutical Chemistry) Rajiv Gandhi University of Health Sciences, Karnataka, Bangalore, India (March 2002)
• Bachelor of Pharmacy Gulbarga University, Gulbarga, India, (July 1997)

Experience:

• Professor, Department of Pharmaceutical Chemistry, RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah, UAE (November 2022-Present)
• Associate Professor, Department of Pharmaceutical Chemistry, RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah, UAE (November 2017-October 2022)
• Assistant Professor, Department of Pharmaceutical Chemistry, RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah, UAE (October 2009-October 2017)
• Associate Professor, Department of Pharmaceutical Chemistry, RMES's College of Pharmacy, Gulbarga, Karnataka, India (September 2007-October 2009)
• Assistant Professor, Department of Pharmaceutical Chemistry at NGSM Institute of Pharmaceutical Sciences, Mangalore, Karnataka, India (October, 2005 - August 2007)
• Lecturer in Pharmaceutical Chemistry at Luqman College of Pharmacy, Gulbarga-2, Karnataka. (November 1997-January 2000)

Courses Taught

• Foundations of Pharmacy (B. Pharm Year 1)
• Pharmaceutical Analysis I & II (B. Pharm Year 1 & 2)
• Medicinal Chemistry (B. Pharm Year 3)
• Innovations & Entrepreneurship in Pharmacy (B. Pharm Year 3)
• Pharmacy Administration (B. Pharm Year 3)
• Complementary & Alternative Medicine (B. Pharm Year 1)
• Advanced Lab Safety & Hazardous Waste Disposal (MS Pharmaceutical Sciences)
• Advanced Pharmaceutical Analysis (MS Pharmaceutical Sciences)

Publications

• Wali AF, Talath S, Alaani NN, Mohamed OI, Alhamadani TH. Evidence-based perspectives on complementary and alternative medicine in cancer treatment: current advances and clinical relevance. J Multidiscip Healthc. 2026;19:629362. doi: 10.2147/JMDH.S629362.
• Wali AF, Talath S, Rangraze IR, El-Tanani M, Khan S. Microbiome‐driven mechanisms in breast cancer: emerging evidence from gut microbial signatures to therapeutic response. Biomed Res Int. 2026;2026(1):8376859. doi: 10.1155/bmri/8376859.
• Talath S, El-Tanani M, Wali AF, Rabbani SA, Bhongande B, Ibraheem W, Avagimyan A, Hoffmann K, Ilias I, Ispas S, Maggio V, Paczkowska A, Rizzo M. Natural supplements in breast cancer therapy: translational evidence, clinical safety, and emerging challenges. Front Oncol. 2026;16:1748136. doi: 10.3389/fonc.2026.1748136.
• Ibraheem W, El-Tanani M, Bhongade B, Talath S, Wali AF, Hoffmann K, Ioannis I, Sorina I, Maggio V, Paczkowska A, Rizzo M. Recent advances in medicinal chemistry on PqsR in Pseudomonas aeruginosa: scaffold optimization, SAR insights, and natural product modulators. Eur J Med Chem. 2026;309:118756. doi: 10.1016/j.ejmech.2026.118756.
• Wali AF, Talath S, Babiker R, El-Tanani M, Rangraze IR, Ibraheem W, Al Aldhaheri Y, Satyam SM, El-Tanani Y. Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials. Front Pharmacol. 2026;17:1764550. doi: 10.3389/fphar.2026.1764550.
• Salama RAA, El-Tanani M, Rabbani SA, Patni M, Bhongade B, Babiker R, Satyam SM, Rangraze IR, Wali AF, Talath S, Abdalla OE. Pathological complete response to Nab-Paclitaxel–containing neoadjuvant regimens in early triple-negative breast cancer: a systematic review and meta-analysis. J Clin Med. 2026;15(18):7321. doi: 10.3390/jcm15187321.
• Ispas S, Maggio V, Rabbani SA, Wali AF, Bhongade BA, Talath S, Rangraze IR, Satyam SM, Avagimyan A, Hoffmann K, Ilias I, Paczkowska A, El-Tanani M, Rizzo M. Mesenteric panniculitis and the gut–mesentery–metabolic axis: a hypothesis-generating narrative review. Biomedicines. 2026;14(9):2017. doi: 10.3390/biomedicines14092017.
• Wali AF, El-Tanani M, Talath S, Rabbani SA, Rangraze IR, Satyam SM, Avagimyan A, Hoffmann K, Ilias I, Ispas S, Maggio V, Paczkowska A, Rizzo M. Antibody–drug conjugates and beyond: next-generation targeted therapies for breast cancer. Cancers (Basel). 2025;17(24):3943. doi: 10.3390/cancers17243943.
• Edwin V, Patni MM, Ravi RK, Muthu P, Talath S, Chaitanya NCSK, Nayagam VE. Junk food consumption and socio-demographic correlates among health sciences students in the UAE. Front Nutr. 2026;13:1742473. doi: 10.3389/fnut.2026.1742473.
• Faizan S, Talath S, Wali AF, Hani U, Haider N, Mandal SP, Kumar BRP. Anticancer potential of novel symmetrical and asymmetrical dihydropyridines against breast cancer via EGFR inhibition: molecular design, synthesis, analysis and screening. RSC Adv. 2024;14(16):11368-11387. doi: 10.1039/D4RA01424C.

Patent

• Bhoomendra A. Bhongade, Sirajunisa Talath. Chiral imidazo[2,1-b][1,3,4]thiadiazole compounds and processes for synthesizing the same. Indian Patent No 373257, July 29, 2021